AVH
data caveat$175M—
AVITA Medical
Medical Devices · Wound care
Commercial-stage regenerative medicine company whose RECELL System delivers FDA-approved Spray-On Skin for burn wounds, full-thickness skin defects, and vitiligo repigmentation.
Data HealthTrials2 of 2 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$175M
Burn Rate
—
Shares Outstanding
153M
Pipeline Assets
9
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther14 May 2026
Financial Results for Quarter Ending 31 March 2026
AVITA Medical reported Q1 2026 financial results with total revenues of $19.3M (up from $18.5M YoY), but operating loss of $8.8M. The company maintains a negative stockholders' equity position of -$23.2M and faces increased debt burden with loan facility at $46.1M.
3M Price
AVH.ASX$1.140-12.3% 3M
Low $1.075High $1.525
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
1 transactionLast 90dNet Buy
Buys1+1 vs prior
Sells0
Buy Value$15k
warningCary G. Vance bought 32d before "Cohealyx I study data readout" ($15,258)
warningCary G. Vance bought 32d before "Final MAC reimbursement coverage" ($15,258)
warningCary G. Vance bought 32d before "7th MAC reimbursement rate publication" ($15,258)
Catalysts (27)· 6 upcoming · 21 past
Cohealyx I study data readout
UpcomingExpectedarrow_upwardHigh30 June 2026
Final MAC reimbursement coverage
UpcomingExpectedarrow_upwardHigh30 June 2026
7th MAC reimbursement rate publication
UpcomingConfirmedremoveMed30 June 2026
PermeaDerm I study data readout
UpcomingExpected
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
2/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 27 tracked
Completed catalysts
✓RECELL GO TGA — AVITA Secures Australia & NZ Clearance for RECELL GO— RECELL GO received TGA certification in Australia and Medsafe WAND listing in New Zealand, enabling commercialization of AVITA Medical's next-generation automated system for preparing RECELL Spray-On Skin for burn and acute wound treatment. Distribution partner Revolution Surgical expects to initiate commercial launch in both markets within weeks.
On time
✓Financial Results for Quarter Ending 31 March 2026— AVITA Medical reported Q1 2026 financial results with total revenues of $19.3M (up from $18.5M YoY), but operating loss of $8.8M. The company maintains a negative stockholders' equity position of -$23.2M and faces increased debt burden with loan facility at $46.1M.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(3)
2 activeClinicalTrials.gov ↗
NAActive Not RecruitingEnrollment stale · 391d
Cohealyx
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
Burn · Trauma Wound · Full Thickness Wounds +1 more
Primary endpoint Time for Cohealyx to generate tissue capable of supporting definitive closure
ENROL41
no manual snapshots — enter via record_enrollment.py
NAActive Not RecruitingEnrollment stale · 474d
PermeaDerm Biosynthetic Wound MatrixFrozen Human Cadaveric Allograft (FHCA)
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds
Surgical Wound · Trauma Wound · Autografts +2 more
RandomizedOpen Label
Primary endpoint Reduction of Cost per Total Body Surface Area (TBSA)
ENROL40
no manual snapshots — enter via record_enrollment.py